Investigational drug · Phase 2
RG002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Human Papillomavirus Associated Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 2/3, Human Papillomavirus Type 16 Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 22, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RG002"
First trial start
2024
Mar 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RG002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Human Papillomavirus Associated Intraepithelial Neoplasia
- Cervical Intraepithelial Neoplasia Grade 2/3
- Human Papillomavirus Type 16 Infection
- Human Papillomavirus Type 18 Infection
Approved drugs for the same conditions: Oncology · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "RG002" as an intervention, largest first.
- A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3Not yet recruiting
RinuaGene Biotechnology Co., Ltd.Industry
NCT06273553 · 39 participants (planned) · Start Mar 2024 · Primary completion Oct 2026
Drug: RG002 injection · For: Human Papillomavirus Associated Intraepithelial Neoplasia; Cervical Intraepithelial Neoplasia Grade 2/3; Human Papillomavirus Type 16 Infection and 1 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.